Maximus (NYSE:MMS) Updates FY 2026 Earnings Guidance

Maximus (NYSE:MMS) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 7.900-8.200 for the period, compared to the consensus EPS estimate of 8.430. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.3 billion.

Maximus Trading Down 0.4%

MMS opened at $63.06 on Thursday. The stock has a market capitalization of $3.31 billion, a P/E ratio of 9.44 and a beta of 0.59. The company has a current ratio of 2.21, a quick ratio of 2.21 and a debt-to-equity ratio of 0.87. Maximus has a 12 month low of $52.73 and a 12 month high of $100.00. The firm’s fifty day simple moving average is $58.77 and its 200 day simple moving average is $67.80.

Maximus (NYSE:MMS) last released its earnings results on Thursday, August 6th. The health services provider reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.01. Maximus had a return on equity of 25.10% and a net margin of 7.02%.Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. As a group, research analysts anticipate that Maximus will post 8.43 EPS for the current fiscal year.

Maximus Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be given a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Friday, August 14th. Maximus’s dividend payout ratio is currently 19.76%.

Analyst Ratings Changes

A number of research firms recently issued reports on MMS. Zacks Research downgraded Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings cut Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 20th. Finally, Wall Street Zen raised Maximus from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Maximus presently has an average rating of “Hold”.

Hedge Funds Weigh In On Maximus

A number of large investors have recently modified their holdings of the business. EP Wealth Advisors LLC acquired a new stake in shares of Maximus in the fourth quarter valued at about $329,000. Empowered Funds LLC boosted its position in Maximus by 266.4% during the fourth quarter. Empowered Funds LLC now owns 9,544 shares of the health services provider’s stock valued at $824,000 after purchasing an additional 6,939 shares during the last quarter. XTX Topco Ltd grew its stake in Maximus by 95.0% in the fourth quarter. XTX Topco Ltd now owns 15,595 shares of the health services provider’s stock valued at $1,346,000 after purchasing an additional 7,599 shares in the last quarter. Voloridge Investment Management LLC increased its position in shares of Maximus by 40.8% during the 4th quarter. Voloridge Investment Management LLC now owns 192,679 shares of the health services provider’s stock worth $16,632,000 after purchasing an additional 55,872 shares during the last quarter. Finally, Oxford Asset Management LLP acquired a new position in shares of Maximus during the 4th quarter worth approximately $1,714,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.